Positive Developments in Mersana Therapeutics’ TNBC Trials and Stable Financial Position Support Buy Rating

LifeSci Capital analyst Charles Zhu maintained a Buy rating on Mersana Therapeutics (MRSN – Research Report) today and set a price target of $3.00.

Charles Zhu’s rating is based on the recent positive developments in Mersana Therapeutics’ clinical trials, particularly the updated data from the Phase 1 dose escalation study focused on triple-negative breast cancer (TNBC) for their B7-H4-targeted antibody-drug conjugate, emiltatug ledadotin (Emi-Le). The new information presented at the 2025 ESMO Breast conference showed an improved response rate in solid tumors at intermediate doses, rising from 23% to 31% compared to the January update. This progress is seen as encouraging, especially with additional confirmed responses in solid tumors, which is significant for Mersana’s focus on TNBC.
Furthermore, Mersana’s financial position is stable, with $102.3 million in cash and equivalents, providing an operating runway into mid-2026. The company is also on track to deliver further Emi-Le data readouts at the ASCO 2025 conference and in the second half of the year for TNBC patients. These factors, combined with strategic restructuring efforts to focus on Emi-Le in TNBC, underpin Charles Zhu’s Buy rating for Mersana Therapeutics.

According to TipRanks, Zhu is an analyst with an average return of -13.2% and a 29.81% success rate. Zhu covers the Healthcare sector, focusing on stocks such as Merus, Protara Therapeutics, and Kura Oncology.